Pediatric Inflammatory Bowel Disease

M11-290

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects with Moderate to Severe Ulcerative
Colitis (AbbVie M11-290)

This is a Phase 3 research study for participants with ulcerative colitis aged 8-17 years old. Participants will be on the study and receive the study investigational medication and/or placebo until the study is completed unless they are removed or voluntarily end participation. It is estimated that participants will participate for approximately 1 year. During this time, participants will be evaluated by the study team weekly from weeks 0-2, bi-weekly from weeks 2-4, every 4 weeks from weeks 4-12, every 6 weeks from weeks 12-18, and every 8 weeks from weeks 18-42 and completion visit at week 52.

 

For more information or eligibility criteria, call our Research Hotline number at 612- 870-5599, OR input the following information and we will follow up with you to discuss your interest:

ATTENTION: This form is not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Calls of this nature will not be answered by email and should be directed to 612-871-1145. In the event of a medical emergency, dial 911. Emails are monitored Monday through Friday during regular business hours.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.